Literature DB >> 1623212

Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors.

G Sava1, S Pacor, G Mestroni, E Alessio.   

Abstract

The effects of two new Ru(III) complexes, [mer-RuCl3(DMSO)2Im] degrees and Na[trans-RuCl4(DMSO)Im], were investigated on primary tumor growth and on the survival time using three solid metastasizing tumors of the mouse: Lewis lung carcinoma, B16 melanoma and MCa mammary carcinoma. Na[trans-RuCl4(DMSO)Im] appears to be the most promising compound, in that: (1) it is soluble in water and therefore easy to handle in comparison with the neutral species [mer-RuCl3(DMSO)2Im]degrees or to the already described BBR2382; (2) similarly to cisplatin, though at a lower level, it reduces tumor growth in its primary site in each tumor model employed; (3) unlike cisplatin, it increases the life span of tumor-bearing hosts in all tumors used, independently of the effects on primary tumor growth; and (4) it is also effective in reducing spontaneous metastasis formation when the effects on primary tumor growth are completely absent. Dimethylsulfoxide (DMSO), used for solubilizing poorly water-soluble compounds (i.e. [mer-RuCl3(DMSO)2Im]degrees) or for stabilizing the compound in the solution before injection (i.e. Na[trans-RuCl4(DMSO)Im]), reduces the anti-tumor potency. Conversely, the antitumor effects of Na[trans-RuCl4(DMSO)Im] are more pronounced in mice hydrated with isotonic saline. We conclude that Na[trans-RuCl4(DMSO)Im] is a good candidate for further investigations aimed at ascertaining the mechanism of the anti-metastatic activity and of the positive effects on survival time of mice bearing solid metastasizing tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623212     DOI: 10.1097/00001813-199202000-00005

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice.

Authors:  G Sava; R Gagliardi; M Cocchietto; K Clerici; I Capozzi; M Marrella; E Alessio; G Mestroni; R Milanino
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

2.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

3.  Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties.

Authors:  G Sava; S Pacor; G Mestroni; E Alessio
Journal:  Clin Exp Metastasis       Date:  1992-07       Impact factor: 5.150

4.  Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.

Authors:  Jana Hildebrandt; Norman Häfner; Daniel Kritsch; Helmar Görls; Matthias Dürst; Ingo B Runnebaum; Wolfgang Weigand
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

5.  Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.

Authors:  G Sava; I Capozzi; K Clerici; G Gagliardi; E Alessio; G Mestroni
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

6.  Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.

Authors:  R Gagliardi; G Sava; S Pacor; G Mestroni; E Alessio
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

7.  Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties.

Authors:  Anna Castellarin; Sonia Zorzet; Alberta Bergamo; Gianni Sava
Journal:  Int J Mol Sci       Date:  2016-08-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.